These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 34009099)

  • 1. A Case of Bilateral Multifocal Choroiditis Associated with BRAF/MEK Inhibitor Use for Metastatic Cutaneous Melanoma.
    Yanagihara RT; Tom ES; Seitzman GD; Saraf SS
    Ocul Immunol Inflamm; 2022; 30(7-8):2005-2009. PubMed ID: 34009099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Ocular toxicity of targeted therapies with MEK inhibitors and BRAF inhibitors in the treatment of metastatic cutaneous melanoma].
    Fauviaux E; Promelle V; Boucenna V; Jany B; Errera MH; Delbarre M; Boucenna W
    J Fr Ophtalmol; 2022 Jun; 45(6):612-618. PubMed ID: 35501194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma.
    Graf NP; Koelblinger P; Galliker N; Conrad S; Barysch M; Mangana J; Dummer R; Cheng PF; Goldinger SM
    J Eur Acad Dermatol Venereol; 2019 Apr; 33(4):686-692. PubMed ID: 30468696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Choroidal Neovascularization in Multifocal Choroiditis after Dabrafenib and Trametinib.
    Albertini GC; Corbelli E; Battaglia Parodi M; Bandello F
    Eur J Ophthalmol; 2017 Nov; 27(6):e184-e186. PubMed ID: 28777388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations.
    Trojaniello C; Festino L; Vanella V; Ascierto PA
    Expert Rev Clin Pharmacol; 2019 Mar; 12(3):259-266. PubMed ID: 30652516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical observation of panniculitis in two patients with BRAF-mutated metastatic melanoma treated with a combination of a BRAF inhibitor and a MEK inhibitor.
    Galliker NA; Murer C; Kamarashev J; Dummer R; Goldinger SM
    Eur J Dermatol; 2015 Apr; 25(2):177-80. PubMed ID: 25788221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravitreal Steroid Treatment for Uveitis Associated with Dabrafenib and Trametinib for Metastatic Cutaneous Melanoma.
    Woltsche N; Kruger MA; Weger M; Wolf IH; Seidel G
    Ocul Immunol Inflamm; 2021 Jul; 29(5):845-847. PubMed ID: 31906779
    [No Abstract]   [Full Text] [Related]  

  • 8. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
    Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion-Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
    Lancet Oncol; 2018 May; 19(5):603-615. PubMed ID: 29573941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.
    Gogas HJ; Flaherty KT; Dummer R; Ascierto PA; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Sileni VC; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Gollerkeri A; Pickard MD; Robert C
    Eur J Cancer; 2019 Sep; 119():97-106. PubMed ID: 31437754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transient MEK inhibitor-associated retinopathy in metastatic melanoma.
    Urner-Bloch U; Urner M; Stieger P; Galliker N; Winterton N; Zubel A; Moutouh-de Parseval L; Dummer R; Goldinger SM
    Ann Oncol; 2014 Jul; 25(7):1437-1441. PubMed ID: 24864047
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Successful rechallenge therapy for BRAF/MEK inhibitor-resistant multiple brain metastases of melanoma.
    Fukushima H; Iwata Y; Saito K; Sugiura K
    J Dermatol; 2021 Aug; 48(8):1291-1295. PubMed ID: 34018641
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Severe pyrexia from nivolumab-resistant advanced melanoma after successful combined therapy with encorafenib plus binimetinib.
    Amagai R; Fujimura T; Kambayashi Y; Sato Y; Tanita K; Ohuchi K; Hashimoto A; Aiba S
    J Dermatol; 2020 Jun; 47(6):654-657. PubMed ID: 32293049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. VKH-like syndrome in the setting of Dabrafenib and Trametinib therapy for BRAF mutant metastatic melanoma: a case report.
    Gunaratnam C; Muzicenco O; Sivagurunathan P; Franzco MH
    J Surg Case Rep; 2024 Mar; 2024(3):rjae104. PubMed ID: 38455982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on BRAF and MEK inhibition for treatment of melanoma in metastatic, unresectable, and adjuvant settings.
    Broman KK; Dossett LA; Sun J; Eroglu Z; Zager JS
    Expert Opin Drug Saf; 2019 May; 18(5):381-392. PubMed ID: 30977681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Choroidal thickening with serous retinal detachment in BRAF/MEK inhibitor-induced uveitis: A case report.
    Kiraly P; Groznik AL; Valentinčič NV; Mekjavić PJ; Urbančič M; Ocvirk J; Mesti T
    World J Clin Cases; 2022 Jul; 10(19):6536-6542. PubMed ID: 35979276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma.
    Rose AAN
    Drugs Today (Barc); 2019 Apr; 55(4):247-264. PubMed ID: 31050693
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma.
    Dimitriou F; Urner-Bloch U; Eggenschwiler C; Mitsakakis N; Mangana J; Dummer R; Urner M
    Eur J Cancer; 2021 Feb; 144():215-223. PubMed ID: 33373866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
    Dummer R; Ascierto PA; Gogas HJ; Arance A; Mandala M; Liszkay G; Garbe C; Schadendorf D; Krajsova I; Gutzmer R; Chiarion Sileni V; Dutriaux C; de Groot JWB; Yamazaki N; Loquai C; Moutouh-de Parseval LA; Pickard MD; Sandor V; Robert C; Flaherty KT
    Lancet Oncol; 2018 Oct; 19(10):1315-1327. PubMed ID: 30219628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of the encorafenib + binimetinib combination in a BRAF mutated metastatic melanoma case report].
    Di Guardo L
    Recenti Prog Med; 2022 Jun; 113(6):28e-30e. PubMed ID: 35758129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tubulointerstitial nephritis and uveitis with bilateral multifocal choroiditis.
    Derzko-Dzulynsky L; Rabinovitch T
    Am J Ophthalmol; 2000 Jun; 129(6):807-9. PubMed ID: 10926997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.